Andro Ranti

Andro Ranti

Auto-generated profile, based on publicly available information

Andro Ranti

Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2026 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
VYVaralee Yodsurang
Varalee Yodsurang
KWKrit Wattanathum
Krit Wattanathum
TSThanate Srimatimanon
Thanate Srimatimanon
KPKrittin Pitinanon
Krittin Pitinanon
ARAndro Ranti
Andro Ranti
ASAlisara Sangviroon Sujarit
Alisara Sangviroon Sujarit
Background: While bleeding is an inherent risk of all anticoagulant therapies, individual susceptibility varies considerably. Rivaroxaban, a direct oral anticoagulant widely used for thromboembolic prevention, is associated with substantial interindividual variability in bleeding risk, posing an ongoing clinical challenge. Objectives: To investigate associations between pharmacogenetic variants in five pharmacokinetic (PK) and nine pharmacodynamic (PD) genes, along with clinical factors, and bleeding outcomes in Thai patients receiving rivaroxaban. Design: A retrospective case–control study was conducted among 91 patients with atrial fibrillation, including 27 who experienced bleeding events. Methods: Genetic variants in PK and PD genes were genotyped using the MassARRAY ® system, and associations between pharmacogenetic variants, clinical factors, and bleeding risk were evaluated using logistic regression analysis. Results: The CT genotype of ABCB1 rs10276036 (C>T) was associated with an increased risk of bleeding. Clinical factors, including prior bleeding history, were also significantly associated with increased bleeding risk. In addition, allele frequency patterns suggested population-specific genetic variation in this Thai cohort. These findings suggest that genetic and clinical factors may jointly contribute to bleeding susceptibility. Conclusion: Bleeding risk in Thai patients receiving rivaroxaban appeared to be influenced by both pharmacogenetic variants, particularly the ABCB1 rs10276036, and established clinical factors. These findings are exploratory and highlight the potential value of integrating genetic and clinical information for risk stratification, pending validation in larger cohorts. Trial registration: As a retrospective non-interventional study, this work was not registered in a clinical trial registry. Ethical approval was obtained (COA No. 1657/2022).